Australia's Nurix Therapeutics Q4 net loss widens

Overview

• Biopharmaceutical firm's fiscal Q4 revenue rose slightly yr/yr

• Company reported a net loss for Q4, widening from the previous year

• Initiated DAYBreak pivotal Phase 2 study for bexobrutideg in relapsed/refractory CLL

Outlook

• Company plans Phase 3 trial for DAYBreak CLL-306 in first half of 2026

• Nurix aims for Accelerated Approval submission for DAYBreak CLL-201 Phase 2 study

• Company continues enrollment in NX-5948-301 Phase 1a/1b trial of bexobrutideg in patients with relapsed or refractory B cell malignancies

Result Drivers

• DAYBREAK INITIATION - Nurix initiated DAYBreak pivotal Phase 2 single-arm study for bexobrutideg in relapsed/refractory CLL, supported by compelling Phase 1 data

• PHASE 1 RESULTS - Bexobrutideg showed 83% objective response rate with median progression-free survival of 22.1 months and median duration of response of 20.1 months across all doses tested

• IRAK4 DEGRADER - Preclinical data for IRAK4 degrader Program showed potential efficacy in autoimmune diseases, supporting further development

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Nurix Therapeutics Inc is $30.00, about 54.6% above its January 27 closing price of $19.41

Press Release: ID:nGNX4HZ53X

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.